A Prospective, Open-label, Multi-center Pilot Study to Evaluate the Safety, Feasibility and Usability of the IDA — CSP-027-21  

Chronic Kidney Disease Stage V Clinical Trial

Official title: A Prospective, Open-label, Cross-over, Multi-center Pilot Study to Evaluate the Safety, Feasibility and Usability of the IDA in Subjects Suffering From a Stage 5 Kidney Disease and Who Are Treated With Peritoneal Dialysis

Status Not yet recruiting

Clinical Trial Summary

This is a multi-center, open label, cross-over clinical study. A total of 15 subjects will be enrolled to use the IDA for every peritoneal dialysis exchange for 14 days. To participate in the study, the subjects must have current CKD5 and have been treated with PD for at least 3 months. The subjects will undergo a single peritoneal dialysis exchange procedure at the PD clinic, under supervision of the medical staff and instructed about its operation. Further exchanges will be performed by the subjects themselves at home.

The study includes three periods:

First period (Observational): 14-day Observational Period. Eligible subjects who sign informed consent will continue with their regular CAPD treatment while performing measurement and recording of dialysate in/out time.

Second period (Interventional): 14-day interventional period, where subjects will perform dialysis exchanges using the IDA according to the below visit schedule.

Third period (Follow up): 14-day follow up period, during which the study staff will call the subject once weekly to inquire about device-related SAEs and any changes to concomitant medications.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Chronic Kidney Disease Stage V
• Kidney Diseases
• Renal Insufficiency, Chronic

• NCT number: NCT05342935
• Study type: Interventional
• Source: liberDi Ltd.
• Contact: Maya Shick
• Phone: 97248228090
• Email: maya@liberdi.com
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 2022
• Completion date: March 2023